glp 1 compounded semaglutide Troubling Findings in Study of

These medications work with your bodys natural systems to help regulate appetite, improve fullness cues, and support more consistent eating habits

Overexpression of FPN1 in neurons significantly reduces mitochondrial iron accumulation, alleviates lipid peroxidation, and improves pathological phenotypes in AD models (Bao et al., 2024

A head-to-head clinical trial (SURMOUNT-5) published in The New England Journal of Medicine in 2025 also demonstrated the superiority of tirzepatide over semaglutide

These pharmacological differences highlight the challenge of pooling these agents together

The Evidence: Primarily studied in animal and in vitro models, showing GLP-1 stimulation and potential appetite-suppressing effects